JCA Pulse › JCA report published
JCA report publishedCamizestrant (Etcamah): EU joint clinical assessment
ER-positive, HER2-negative locally advanced or metastatic breast cancer, with a CDK4/6 inhibitor, on detection of an ESR1 mutation during first-line endocrine therapy, without progression
- Regulatory review
- CHMP opinion
- EU authorised
- JCA report published
Overview
- Company
- AstraZeneca
- Therapy area
- Solid tumours · Breast
- Indication
- ER-positive, HER2-negative locally advanced or metastatic breast cancer, with a CDK4/6 inhibitor, on detection of an ESR1 mutation during first-line endocrine therapy, without progression
- Product type
- Chemical
- EC marketing authorisation
- 20 Jul 2026
- JCA report published
- 6 Nov 2026
- JCA assessor
- Federation of Social Insurances, Austria
- Co-assessor
- INAMI-RIZIV, Belgium
- Pivotal evidence
- SERENA-6 (phase 3, double-blind RCT, n=315)
Scope
From the published report
The JCA report set out 5 PICOs across 3 populations.
Three populations: the full indication, women, and men. Seven PICOs at first, reduced to five when the claimed indication was narrowed in January 2026. Comparators: CDK4/6 inhibitor + non-steroidal AI (continuing first-line therapy), CDK4/6 inhibitor + fulvestrant, and AI monotherapy.
JCA Pulse forecast 1–2 PICOs. The core PICO, the comparison with continued AI + CDK4/6 inhibitor, matched the report; the separate populations for women and men, and the fulvestrant and AI monotherapy comparators, were not anticipated. The forecasts for all pending assessments were revised on 10 November 2026 to reflect this.
Evidence
How the evidence covered the scope
Comparative evidence informed 2 of the 5 PICOs, both from one SERENA-6 analysis. Pro breaks down how the evidence covered each one, and what it means for later submissions.
Countries
National translator and outlook
Austria and Belgium led the joint assessment. Pro explains what the JCA means for the national route in each of 31 markets, with 3 national records already in place.
Sources
- European Commission: JCA report on camizestrant (Etcamah)
- JCA summary report (PDF)
- European Commission list of completed JCAs
Last checked 10 November 2026. Compiled from public sources; check them for the latest position. Forecasts are Evidaxia’s independent view, not official assessments.
From Evidaxia
- EU JCA dossiers and PICO scopingSupport from PICO scoping to the dossier
- JCA PICO scoping: process and preparationHow assessors set the scope
- EU JCA timelineEvery upcoming milestone
Also in Solid tumours
- Bifikafusp alfa / onfekafusp alfa (Nidlegy)Melanoma, neoadjuvant
- CosibelimabCutaneous squamous cell carcinoma
- DaraxonrasibMetastatic pancreatic cancer
- Ensartinib (Gevalka)ALK-positive NSCLC
- FuzuloparibmCRPC, first line
- LirafugratinibFGFR2-altered cholangiocarcinoma